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Children are not small adults, but rather a distinct and heterogeneous patient group with specific 
therapeutic needs. Child development entails dynamic processes inherent to growth from birth 
into adulthood, and children face a scope of diseases different than those of adults. Accordingly, 
safe and effective paediatric pharmacotherapy requires medicines adjusted to the needs, 
acceptability and preferences (of each subpopulation) of children.  
In the introduction (chapter 1) we refer to the global progress made in improving child survival 
and health between 1990 and 2015. Although the 53 per cent drop in child under-five mortality is 
substantial, it is not enough to meet the UN Millennium Development Goal (MDG) 4 of a two-
thirds reduction. About half of the reduction in child under-five deaths comes from better 
prevention and management of pneumonia, diarrhoea, measles, and malaria. Many of these 
conditions are preventable or treatable with proven interventions, which include the use of 
paediatric medicines and vaccines. But, there is still a major challenge because appropriate 
medicines as part of the treatment options are not available. 
The failure to meet the special needs for medicines in children was outlined in the Priority 
Medicines for Europe and the World Report in 2004. This report emphasized the importance of 
conducting specific research on medicines in children, and made recommendations to support 
paediatric drug development, including the neglected area of age-appropriate formulations. 
Beyond the development of child-specific medicines, it is equally important that these medicines 
are made accessible, and that they are used rationally within healthcare systems. In chapter 1 we 
highlight the optimization of antibiotic use as an important aspect of rational use of medicines, 
given the emergence and spread of antibiotic resistance, and the extensive misuse of antibiotics 
globally. While antibiotics remain the most widely prescribed medicines in children, systematic 
data on use of antibiotics in children is very sparse, especially for resource-restricted countries.  
Fortunately, all stakeholders have become progressively aware of the relevance of more 
evidence-based paediatric pharmacotherapy and drug development, although much remains to be 
done. In this landscape where further action is required to address public health needs in 
children, the aim of the present thesis was to document recent advancements with respect to 
priority medicines for children, and conduct additional research on age-appropriate formulations 
and use of antibiotics in children across different settings.  
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Chapter 2 presents the update of the 2004 Background paper on Priority medicines in children 
for Europe and the world. The unmet needs for medicines in children continue to exist due to 
children's particular needs in terms of drug delivery mechanism and/or formulations, mostly at 
younger age. Some of the priority diseases for which child-specific medicines are lacking as a 
treatment option, include: HIV/AIDS, tuberculosis, cancers, rare diseases, malaria, pneumonia, 
cardiovascular diseases, infections due to antibacterial resistance, and many neglected tropical 
diseases. In addition, some unmet needs for medicines in children are also related to the fact that 
more research is required to develop new therapies for diseases and conditions restricted to 
children, such as preterm births, neonatal sepsis, and birth asphyxia.  
In response to the lack of paediatric medicines, the European Union implemented the Paediatric 
Regulation in 2007, combining legal requirements with incentives for companies to test, 
authorize, and formulate medicines for use in children. It has created a new structured framework 
to screen every new adult product for its potential paediatric value, and promote capacity 
building and closer cooperation in the area of paediatric medicines research. The initial progress 
includes increasing numbers of paediatric clinical trials, and intensified development of 
medicines for children. Nonetheless, therapeutic areas addressed by the industry seem to be more 
aligned with adult drug development than with unmet public health needs in children. To guide 
the efforts towards significant benefits for children, the European Medicines Agency has 
produced priority medicines lists to highlight areas with substantial off-label use in children and 
gaps in paediatric data. These lists need to be accompanied by appropriate reward systems for 
investment in paediatric drug. The commercial viability of paediatric medicines might be 
improved by an increased market size (e.g. global scale, inclusion of geriatric patients and adults 
with swallowing difficulties), new incentives schemes (e.g. for off-patent drugs), and public-
private partnerships that support the development of orphan drugs and other less profitable 
niches.  
In chapter 3 we focus on age-appropriate formulations for children. In chapter 3.1 the progress 
in this area is illustrated by the shifting trends towards novel age-appropriate oral formulations 
with dose flexibility: mini-tablets, chewable and orodispersible tablets for younger children, and 
dosage forms dispersible into liquids or mixed with food. This is in line with the consensus 
reached at the WHO expert forum in 2008 that flexible solid oral dosage forms have advantages 
over traditional liquid preparations, particularly for children of younger age and those living in 
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developing countries. Nevertheless, despite the research on novel paediatric products, there are 
limited patient outcome studies with clinical feedback (e.g. impact on side effects, tolerability 
and administration errors) to support ongoing technological advances for children. Moreover, 
there have been examples of low-uptake levels of novel solid formulations, due to their high cost 
implications, or common unfamiliarity with new formulations. Thus, patient and health care 
professionals' education about novel formulations, and evidence-based research on added value 
for children (i.e. efficacy, safety, patient acceptability, preferences and adherence) are needed to 
link their development to the acceptance in clinical practice.  
Since the lack of medicines most acutely affects children living in low-resource settings, there 
has been a global action focusing on appropriate medicines to treat diseases of high burden in 
childhood. Consequently, the WHO Essential Medicines List for Children (EMLc) was released 
in 2007 to stress the special needs for medicines in children, and promote the inclusion of 
paediatric medicines in national procurement programs. In chapter 3.2 we compare the age-
appropriate antibiotic formulations on relevant formularies from the United Kingdom, Australia 
and the Netherlands versus the WHO EMLc in order to identify potential new paediatric 
products for inclusion on the EMLc. All the formulations on comparator lists that differed from 
the EMLc formulations in relation to administration routes, dosage forms and/or drug strengths 
were evaluated for their added clinical values as well as costs. The analysis identified seven oral 
and two parenteral formulations on comparator lists that may offer clinical benefits for low-
resource settings, including simplified administration and increased dosing accuracy. On the 
other hand, the complexity of both procuring and managing multiple strengths and formulations 
also needs to be considered. Similarly, the barriers for the implementation of new formulations at 
the field level should be considered, as listing in the WHO EML does not always translate into 
demand for the medicines.  
There are equal challenges to ensure not only that medicines for children are developed and 
made available, but also that they are used in a rational manner. So, understanding the extent of 
medicines  consumption is an essential starting point to monitor and improve prescribing and use 
patterns. The focus in chapter 4 is mostly on challenges of measuring and improving the use of 
antibiotics, due to their wide use in children, and the impact of infections on child morbidity and 
mortality. In chapter 4.1 we assess the trends in prescribing patterns for acute childhood 
infections in primary care in developing and transitional countries between 1990 and 2009, and 
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analyze the effects of interventions to improve their treatment. Data were extracted from the 
WHO Medicines Use Database, and consisted of 344 paediatric studies conducted in 78 
countries. The results showed a mixed progress, with most of the treatment aspects of infections 
remaining sub-optimal over time. There was an improvement in the treatment of diarrhoea, 
reflecting an increased use of oral rehydration salts, although the trend was not statistically 
significant (from 14% pre-1990 to 60% in 2006–2009, p=0.57). However, the rates of treating 
pneumonia with appropriate antibiotics remained below 80% over time. Also, there was a non-
significant trend towards increased inappropriate use of antibiotics to treat viral upper respiratory 
tract infections (URTI), from 42% pre-1990 to 72% in 2006–2009 (p=0.07). Of the 226 
intervention groups included to improve use of medicines, only 44 (19%) were in studies with a 
methodologically appropriate design. Multi-component interventions resulted in larger 
improvements than single-component ones. The median effect size indicated a 28% 
improvement with community case-management, an 18% improvement with provider education 
combined with consumer education, but only 9% improvement with provider education alone. 
The solutions to improve antibiotic use need to adopt the cross-cutting approach, and restructure 
health systems to “institutionalize” the promotion of the rational use of medicines. Sound 
standard systems to monitor medicines and antibiotic use are also essential, as they are currently 
lacking in many low- and middle-income countries. 
In chapter 4.2 we examined general practitioners' adherence to treatment guidelines for 
paediatric fever, acute respiratory and ear infections in relation to antibiotic prescribing in the 
Netherlands during 2010-2012, and explored potential variations across practices. The data on 
diagnoses and prescriptions for children were derived from the electronic health records-based 
NIVEL Primary Care Database. Half of the episodes with respiratory and ear infections with 
restrictive prescribing policy (acute otitis media - AOM, strep throat, sinusitis and tonsillitis) and 
65% of episodes with pneumonia were treated with antibiotics. This shows a relatively 
conservative use of antibiotics in the Netherlands for these infections. The figures could be used 
as indicators of attainable prescribing rates by other EU countries with higher antibiotic 
consumption. One potential aspect of concern is that 40% of children with acute bronchitis were 
prescribed antibiotics, opposite to the guidelines. The second challenge is that between 15% and 
50% of cases with any of the diagnoses were not prescribed their first-choice antibiotics, with 
adherence being particularly low for narrow-spectrum penicillins. Moreover, we found marked 
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variations in antibiotic prescribing by practices, especially for first-choice antibiotics. This 
suggests that progress may be achieved by targeting practices with lower adherence rates to 
guidelines for antibiotic prescribing. 
In chapter 4.3 we further explore age-specific antibiotic prescribing patterns, in terms of degree 
of prescribing per diagnosis and choice of antibiotics, by stratifying children from previous study 
in three age groups (0-4/5-11/12-17 years). The results show that for bronchitis more antibiotic 
prescriptions were found in episodes of adolescents compared to children aged 0-4 and 5-11 
years (52.0% vs. 42.4% and 42.7%). Likewise, more adolescents were prescribed antibiotics for 
diagnoses that require antibiotics (i.e. strep throat, pneumonia, and tonsillitis) except for AOM. 
In contrast, underuse of narrow-spectrum penicillins was mostly seen in the 0-4 years age group 
than in age groups 5-11 years and adolescents (strep throat: 60.9% vs. 63.6% and 72.0%, and 
tonsillitis: 33.1% vs. 45.9% and 67.9%). These two studies indicate the areas in which there is a 
room for improvement in antibiotic prescribing, even in the Netherlands. Future efforts to 
improve the disease-specific antibiotic use may consider prescribers' training in communication 
skills to better manage patient pressure, and use of rapid diagnostic tests that differentiate viral 
from bacterial lower tract infections. More research should focus on the barriers to use first-
choice antibiotics, particularly in younger children.  
The aim of the study presented in chapter 4.4 was to investigate the aspect of self-medication 
with antibiotics for children in Macedonia, and analyse the impact of national interventions on 
parental knowledge on antibiotic use, and self-medication. The interventions had a multifaceted 
approach and consisted of: mass media (TV) campaign on appropriate antibiotic use, discussions 
with parents at kindergarten on respiratory infections and antibiotic use, and seminars for health 
workers on the management of respiratory infections and appropriate antibiotic prescribing. Data 
were collected through a structured questionnaire applied to 1203 parents over the three years 
period (2014 - 2016). We found that the parental knowledge of antibiotics in Macedonia was 
similar to average knowledge levels in adults across the EU. More than 80% of parents knew that 
inappropriate use of antibiotics could lead to their inefficacy or side effects, and that antibiotics 
could kill bacteria. Around 40% of parents wrongly believed that antibiotics were effective 
against viruses and common URTIs. The results showed that parental knowledge on antibiotics 
did not change significantly after the interventions. In terms of self-medication, 20% of the 
parents and 10% of the children who received antibiotics in previous year used over-the-counter 
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or left-over antibiotics at baseline. The parental self-medication rates did not change during or 
after the interventions, while children's rates dropped to 5% during the intervention, but 
increased again to 9% in 2016. This implies a need for continuous health education, or at least 
repetitive actions to improve public knowledge and actions on appropriate antibiotic use. This 
should be followed by restrictive measures for prescription-only medicines, and a cooperation 
with pharmacists to attain sustainable changes in antibiotic use across the health system.  
In the general discussion in chapter 5 we present key findings of our studies and discuss these in 
regards to challenges and progress for the development of age-appropriate paediatric medicines, 
as well as antibiotic use in children across different regions and income levels.  
This thesis documents how the practice of developing, selecting and using paediatric medicines 
has evolved within recent paediatric regulatory frameworks and global initiatives to provide 
better medicines for children. Progress and concerted efforts have been made to improve the 
therapies available for children, and novel age-appopriate formulations have become available on 
the market. However, unmet therapeutic needs continue to exist, and further steps in paediatric 
drug research, based on continual prioritisation process, better use of novel technologies for 
adults, and clinical feedback, are needed.  
On equal importance, this thesis evaluates antibiotic use in children across different healthcare 
and income settings. Our results are expected to lead to better understanding of both appropriate 
prescribing patterns and areas for concerns, and the range of interventions implemented to 
improve antibiotic use in children. The studies have shown that, to identify areas for 
improvements, more emphasis is needed on measuring antibiotic use in resource-restricted 
settings, and self-medication practices, where data are scarce. Much work remains to be done, 
and solutions need to focus on multifaceted and multilevel interventions that define local 
barriers, and integrate the promotion of the rational use of antibiotics for children within health 
systems. 
 
 
 
